Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Haw ParHAWPF 83 Debt-to-EBITDA is 0.17 as of Dec. 2025, which is 31% above its 10-year median of 0.13. GuruFocus rates HAWPF with a GF Score™ of 83/100 and a GF Value™ of $9.27 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 690 Drug Manufacturers companies, Haw Par ranks better than 82.46% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Haw Par's Debt-to-EBITDA or its related term are showing as below:
HAWPF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.01 Med: 0.13 Max: 0.32
Current: 0.16
During the past 13 years, the highest Debt-to-EBITDA Ratio of Haw Par was 0.32. The lowest was 0.01. And the median was 0.13.
HAWPF's Debt-to-EBITDA is ranked better than 82.46% of 690
companies
in the Drug Manufacturers industry
Industry Median: 1.65
vs HAWPF: 0.16
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Haw Par Debt-to-EBITDA Related Terms
Haw Par Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Haw Par's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAWPF vs LLY, JNJ, ABBV: Debt-to-EBITDA Comparison
For the Drug Manufacturers - General subindustry, Haw Par's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Haw Par Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Haw Par's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Haw Par's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Haw Par (HAWPF) has a Debt-to-EBITDA of 0.17 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Haw Par. This is 31% above median its historical median of 0.13. Over the past decade, Haw Par's Debt-to-EBITDA has ranged from 0.01 to 0.32. According to the industry distribution chart, Haw Par ranks #121 out of 690 companies in the Drug Manufacturers industry, placing it in the top 17.5%.
Is Haw Par's Debt-to-EBITDA too high?
Haw Par's current Debt-to-EBITDA of 0.17 is 31% above median its 10-year median of 0.13. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.32. The Drug Manufacturers industry median Debt-to-EBITDA is 1.65. Haw Par's value of 0.17 is 89.7% below this industry median. Based on the distribution chart, Haw Par ranks #121 out of 690 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Haw Par has a GF Score™ of 83/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Haw Par's Debt-to-EBITDA compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Haw Par ranks #121 out of 690 companies for Debt-to-EBITDA. This places Haw Par in the top 18% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.65. Haw Par's value of 0.17 is 89.7% below this benchmark. Historically, Haw Par's own Debt-to-EBITDA has ranged from 0.01 to 0.32 over the past decade. While the company's 10-year median is 0.13 vs. the industry median of 1.65, Haw Par has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.65, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Haw Par's current Debt-to-EBITDA of 0.17 is 89.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Haw Par. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Haw Par's current Debt-to-EBITDA is 0.17, which is 31% above median its own 10-year median of 0.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haw Par stock overvalued right now?
Based on GuruFocus' analysis, Haw Par (HAWPF) is currently considered Significantly Overvalued. The stock's GF Value™ is $9.27, compared to a current price of $12.58 — trading 35.7% above its estimated fair value. The current Debt-to-EBITDA is 0.17, which is 31% above median its 10-year median of 0.13 and 89.7% below the Drug Manufacturers industry median of 1.65. Haw Par's overall GF Score™ is 83/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Haw Par (HAWPF), the current Debt-to-EBITDA is 0.17 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Haw Par (HAWPF) Overvalued in 2026?
Based on GuruFocus' analysis, Haw Par stock appears to be overvalued.
The current stock price of $12.58 is trading 35.7% above its estimated GF Value™ of $9.27.
GuruFocus considers Haw Par to be Significantly Overvalued.
Key valuation signals for HAWPF:
Debt-to-EBITDA: 0.17 (31% above median its 10-year median of 0.13)
GF Value™: $9.27 vs. price of $12.58 (35.7% above fair value)
Industry Position: 89.7% below the Drug Manufacturers median (#121 of 690)
No single metric tells the full story. See the HAWPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Haw Par Corp Ltd is a drug manufacturing company that operates multiple brands. The company is to expand its core businesses through product brand extension, strategic alliances, and exploring potential acquisitions. Its operating segments include the Healthcare segment, Investments segment, Property segment, and Leisure segment. The company generates the majority of its revenue from the Healthcare segment. Its Healthcare segment manufactures and distributes topical analgesic products under the Tiger Balm and Kwan Loong brands. Geographically, it generates key revenue from the other ASEAN and other Asian countries.
83GF Score
Get the complete analysis for HAWPF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAWPF has been successfully added to your 
